Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Executive Summary
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S
You may also be interested in...
Markham’s new gig
Former Aventis Vice Chairman and Chief Operating Officer Richard Markham joins Care Capital, a Princeton, N.J.-based venture capital firm focusing on later stage investments. Markham was one of several Aventis senior executives to depart after the company was acquired by Sanofi (1"The Pink Sheet" Sept. 6, 2004, p. 3). He joins former SmithKline Beecham CEO Jan Leschly and Novartis CEO-Pharmaceuticals Jerry Karabelas, PhD, who both serve as partners of the venture capital firm. Prior to Markham's tenure at Aventis (and predecessor companies), he spent 20 years at Merck and was the company's first choice to replace CEO Roy Vagelos, MD, when he retired in 1993; he could be an intriguing choice to replace CEO Ray Gilmartin when he retires in 2006 (2"The Pink Sheet" Oct. 18, 2004, p. 4). However, Markham said he intends to remain in the venture capital industry on a permanent basis...
Markham’s new gig
Former Aventis Vice Chairman and Chief Operating Officer Richard Markham joins Care Capital, a Princeton, N.J.-based venture capital firm focusing on later stage investments. Markham was one of several Aventis senior executives to depart after the company was acquired by Sanofi (1"The Pink Sheet" Sept. 6, 2004, p. 3). He joins former SmithKline Beecham CEO Jan Leschly and Novartis CEO-Pharmaceuticals Jerry Karabelas, PhD, who both serve as partners of the venture capital firm. Prior to Markham's tenure at Aventis (and predecessor companies), he spent 20 years at Merck and was the company's first choice to replace CEO Roy Vagelos, MD, when he retired in 1993; he could be an intriguing choice to replace CEO Ray Gilmartin when he retires in 2006 (2"The Pink Sheet" Oct. 18, 2004, p. 4). However, Markham said he intends to remain in the venture capital industry on a permanent basis...
Merck CEO Search Expands: Is Company Now A Turnaround Story?
Merck is expanding its CEO succession search while revising the job description to take into account the challenges posed by the Vioxx withdrawal